|
KMID : 1036920170220010015
|
|
Annals of Pediatric Endocrinology & Metabolism
2017 Volume.22 No. 1 p.15 ~ p.26
|
|
|
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
|
|
Lee Seung-Ah
Lee Dong-Yun
|
|
|
Abstract
|
|
|
|
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary to develop new drugs, one of which is a glucagon-like peptide-1 (GLP-1) based therapy. GLP-1 has been shown to ameliorate diabetes-related conditions by augmenting pancreatic β-cell insulin secretion and having the low risk of causing hypoglycemia. Because of a very short half-life of GLP-1, many researches have been focused on the development of GLP-1 receptor (GLP-1R) agonists with long half-lives such as exenatide and dulaglutide. Now GLP-1R agonists have a variety of dosing-cycle forms to meet the needs of various patients. In this article, we review the physiological features of GLP-1, the effects of GLP-1 on T2D, the features of several GLP-1R agonists, and the therapeutic effect on T2D.
|
|
|
KEYWORD
|
|
|
Type 2 diabetes, Glucagon-like peptide-1, Glucagon-like peptide-1 receptor, GLP-1R agonist, GLP-1R agonist clinical trials
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|